Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 1977;56:114-118

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Carvalho, A. C.
Right arrow Articles by Colman, R. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Carvalho, A. C.
Right arrow Articles by Colman, R. W.

Circulation, Vol 56, 114-118, Copyright © 1977 by American Heart Association


ARTICLES

Effect of clofibrate on intravascular coagulation in hyperlipoproteinemia

AC Carvalho, RS Lees, RA Vaillancourt and RW Colman

Intravascular coagulation (IVC) was evaluated in 19 patients with type II and 11 with type IV hyperlipoproteinemia before and after clofibrate therapy by measurements of soluble fibrin complexes (SFC) in plasma; fibrinolysis was estimated by quantitation of fibrin (ogen) degradation products in serum. Untreated type II and type IV patients had increased SFC (P less than 0.01). The former also had activation of the intrinsic coagulation pathway as evidenced by decreased plasma prekallikrein (P less than 0.001), kallikrein inhibitors (P less than 0.001), and factor XII (P less than 0.02). Although clofibrate treatment of the type II patients did not change plasma lipids, it decreased intravascular coagulation, apparently via decreased factor XII activation and stimulation of fibrinolysis. In contrast, treated type IV patients had unchanged SFC and FDP levels, despite decreased plasma triglycerides (P less than 0.01). Clofibrate-induced changes in blood coagulation are independent of lipid-lowering. Clofibrate therapy decreases intravascular coagulation in type II patients and may help to prevent thromboembolic sequelae.


This article has been cited by other articles:


Home page
JAMAHome page
K. M. McIntyre
Cardiopulmonary Resuscitation and the Ultimate Coronary Care Unit
JAMA, August 1, 1980; 244(5): 510 - 511.
[Abstract] [PDF]


Home page
Arch Intern MedHome page
K. M. McIntyre, A. F. Parisi, R. Benfari, A. H. Goldberg, and J. E. Dalen
Pathophysiologic Syndromes of Cardiopulmonary Resuscitation
Arch Intern Med, July 1, 1978; 138(7): 1130 - 1133.
[Abstract] [PDF]